Invasive disease with non-typhoidal Salmonella in SSA is associated with increasing antibiotic resistance (AMR) and has been classified by the World Health Organization as high priority for developing new antibiotics. Despite high case fatality rates, particularly in children <5 years of age in SSA countries, no vaccine is currently available. The burden caused by NTS infections and increasing AMR strongly encourage for prompt development of an effective vaccine. A novel vaccine, is currently being developed by GSK Biologicals and GSK Vaccines Institute for Global Health, targeting the serovars Typhimurium and Enteritidis, the most common causative agents of African invasive NTS. Within a large consortium, a paediatric Phase I/II study will be launched early in 2021 in Ghana. The focus of our group will be on antibiotic resistant genotypes of iNTS-causing Salmonella strains. The information gained will not only inform on circulating Salmonella serovars and genotypes but will also inform on the development of AMR pathogens in SSA.



Principal Investigators (PIs)

Prof Richard Phillips 
(Principal Investigator, KNUST, KCCR, Ghana)

+233 2091 40451


Dr. Denise Dekker

Phone: +49 40 42818-521 

Fax: +49 40 42818-512 


Quick Links

Related Projects

  • Genetic adaptation of Salmonella enterica in human and animal reservoirs in sub-Saharan Africa

  • Antibiotic resistant enteric pathogens in human and animal reservoirs

  • Paediatric Phase I/II study of a vaccine against invasive non-typhoidal salmonellosis in sub-Saharan Africa

  • Development of standardized AMR laboratories for AMR surveillance in sub-Saharan Africa

  • „One Health“: AMR in environmental reservoirs and colonizing antibiotic resistant bacteria“-Improving antibiotic use in West Africa: exploring current situation and developing strategies for behavior change